Biocytogen’s BD & Licensing team will attend and present at the upcoming ChinaBio virtual conference on November 8-11, 2022.

The company will give an oral presentation with the title of “Introduction of Biocytogen’s pipeline assets, innovative fully human antibody RenMice platform and Project Integrum for antibody discovery against 1000+ potential targets”. The talk will introduce Biocytogen’s clinical asset YH003 (CD40 antibody) and preclinical assets YH008 (PD-1×CD40 BsAb), YH006 (CTLA-4×OX40 fully human BsAb) and YH013 (EGFR×MET BsADC). The talk will also highlight the latest progress of Project Integrum and introduce the company’s five proprietary RenMice^TM-based fully human antibody discovery platforms, which are designed to facilitate the discovery of monoclonal antibodies, bispecific antibodies, bispecific ADCs, TCR-mimic antibodies and antibodies targeting GPCRs. In addition, the company's flexible business collaboration models and collaboration progress will be introduced.

Biocytogen’s attendees will also host one-on-one partnering meetings. Our experts look forward to discussing licensing and co-development opportunities with you.

For questions, please contact us at BD-Licensing@biocytogen.com.

To reserve a one-on-one meeting with us via PartneringONE, click here.

Log in to watch the presentation (only in English), click here.